... with light-chain (AL) and transthyretin (ATTR) cardiac amyloidosis (CA) are undetermined. Methods: A single-center analysis of clinical, laboratory, imaging, and angiographic characteristics of CA cohort was performed. Results: Included were 98 CA patients (43 AL, 47 wtATTR, 8 mutant ATTR). Eighteen patients...

...Brendan Wisniowski; Ashutosh Wechalekar Amyloidosis is a general term for diseases characterised by the deposition of insoluble amyloid fibrils in organs or tissues, leading to organ dysfunction and, in many cases, death. Amyloid fibrils are derived from soluble precursor proteins, with the number...

...Foteini Theodorakakou; Despina Fotiou; Meletios A. Dimopoulos; Efstathios Kastritis Amyloidosis comprises a diverse group of diseases characterized by misfolding of precursor proteins which eventually form amyloid aggregates and preceding intermediaries, which are deposited in target tissues...

... before specific therapy can be implemented and the current methods are briefly summarized. A brief overview of the target organ involvement by amyloid type is also included. Key Messages: (1) Early diagnosis of amyloidosis continues to pose a significant challenge and requires the participation of many...

...Paolo Milani; Giovanni Palladini The vast majority of patients with light-chain (AL) amyloidosis are not eligible for stem cell transplant and are treated with conventional chemotherapy. Conventional regimens are based on various combinations of dexamethasone, alkylating agents, proteasome...

...Lærke Marie Nelson; Finn Gustafsson; Peter Gimsing Background/Aims: Immunoglobulin light-chain (AL) amyloidosis is a systemic disorder that causes progressive organ dysfunction. The optimal treatment strategy requires accurate patient stratification with an emphasis on the extent of cardiac...

...Jameel Muzaffar; Lakshmikanth Katragadda; Sajjad Haider; Al-Ola Abdallah; Elias Anaissie; Saad Z. Usmani Waldenström's macroglobulinemia (WM) is increasingly being associated with amyloidosis particularly of the amyloid light-chain variety. We report on one of the few cases of WM associated...

...Toshio Shigekiyo; Masaaki Kosaka; Yasumi Shintani; Hiroyuki Azuma; Yasuhiko Iishi; Shiro Saito The mechanism of inhibition of fibrin monomer polymerization was studied in a patient with primary amyloidosis. Thrombin and reptilase times of the patient’s purified fibrinogen (Fbg) were remarkably...

...Leonidas Christou; Eleftheria Chr. Hatzimichael; Florentia Sotsiou-Candila; Konstantinos Siamopoulos; Konstantinos L. Bourantas We report a case of a 39-year-old man with λ-light-chain multiple myeloma, nephrotic syndrome due to λ-light-chain deposition disease in kidneys and amyloidosis in other...